HK1210174A1 - Serine threonine kinase inhibitors for the treatment of hyperproliferativediseases - Google Patents
Serine threonine kinase inhibitors for the treatment of hyperproliferativediseasesInfo
- Publication number
- HK1210174A1 HK1210174A1 HK15111084.7A HK15111084A HK1210174A1 HK 1210174 A1 HK1210174 A1 HK 1210174A1 HK 15111084 A HK15111084 A HK 15111084A HK 1210174 A1 HK1210174 A1 HK 1210174A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- hyperproliferativediseases
- treatment
- kinase inhibitors
- threonine kinase
- serine threonine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261693671P | 2012-08-27 | 2012-08-27 | |
| PCT/US2013/056876 WO2014036015A1 (en) | 2012-08-27 | 2013-08-27 | Serine/threonine kinase inhibitors for the treatment of hyperproliferative|diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1210174A1 true HK1210174A1 (en) | 2016-04-15 |
Family
ID=49118823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15111084.7A HK1210174A1 (en) | 2012-08-27 | 2015-11-10 | Serine threonine kinase inhibitors for the treatment of hyperproliferativediseases |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9388171B2 (pt) |
| EP (1) | EP2888247B1 (pt) |
| JP (1) | JP6378182B2 (pt) |
| KR (1) | KR20150047597A (pt) |
| CN (1) | CN105143200B (pt) |
| AR (1) | AR092253A1 (pt) |
| BR (1) | BR112015004548A2 (pt) |
| CA (1) | CA2882750A1 (pt) |
| HK (1) | HK1210174A1 (pt) |
| MX (1) | MX369989B (pt) |
| RU (1) | RU2644947C2 (pt) |
| TW (1) | TW201408658A (pt) |
| WO (1) | WO2014036015A1 (pt) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012118850A1 (en) | 2011-02-28 | 2012-09-07 | Array Biopharma Inc. | Serine/threonine kinase inhibitors |
| CN103958502B (zh) | 2011-08-04 | 2016-02-10 | 阵列生物制药公司 | 作为丝氨酸/苏氨酸激酶抑制剂的喹唑啉化合物 |
| PL3321262T3 (pl) | 2012-03-01 | 2021-06-28 | Array Biopharma, Inc. | Inhibitory kinaz serynowo/treoninowych |
| NZ703852A (en) | 2012-07-27 | 2018-03-23 | Biogen Ma Inc | Atx modulating agents |
| EP2909206A1 (en) | 2012-10-16 | 2015-08-26 | F. Hoffmann-La Roche AG | Serine/threonine kinase inhibitors |
| US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| KR102359759B1 (ko) | 2013-12-06 | 2022-02-09 | 제넨테크, 인크. | 세린/트레오닌 키나제 저해제 |
| JP6642942B2 (ja) | 2013-12-30 | 2020-02-12 | アレイ バイオファーマ、インコーポレイテッド | セリン／トレオニンキナーゼ阻害剤 |
| CN105848723B (zh) | 2013-12-30 | 2019-08-02 | 基因泰克公司 | 丝氨酸/苏氨酸激酶抑制剂 |
| ES2700200T3 (es) * | 2014-12-22 | 2019-02-14 | Lilly Co Eli | Inhibidores de ERK |
| MX2018012471A (es) | 2016-04-15 | 2019-02-21 | Genentech Inc | Metodos de diagnostico y terapeuticos para el cancer. |
| CN106749117B (zh) * | 2016-11-29 | 2018-10-09 | 北京怡力生物科技有限公司 | 一种3-氨基甲基四氢呋喃的制备方法 |
| CR20190424A (es) | 2017-03-30 | 2019-11-04 | Hoffmann La Roche | Isoquinolinas como inhibidores de hpk1 |
| EP3640242B1 (en) * | 2017-06-16 | 2023-04-19 | Hitgen Ltd. | Rock-inhibiting compound and uses thereof |
| KR20200041387A (ko) | 2017-09-08 | 2020-04-21 | 에프. 호프만-라 로슈 아게 | 암의 진단 및 치료 방법 |
| WO2019158579A1 (en) | 2018-02-13 | 2019-08-22 | Vib Vzw | Targeting minimal residual disease in cancer with rxr antagonists |
| CN108558869B (zh) * | 2018-05-10 | 2019-04-09 | 西安培华学院 | 用于治疗肝癌的化合物及其制剂 |
| TW202019905A (zh) * | 2018-07-24 | 2020-06-01 | 瑞士商赫孚孟拉羅股份公司 | 異喹啉化合物及其用途 |
| US11612606B2 (en) | 2018-10-03 | 2023-03-28 | Genentech, Inc. | 8-aminoisoquinoline compounds and uses thereof |
| GEP20237561B (en) | 2019-04-02 | 2023-10-25 | Array Biopharma Inc | Protein tyrosine phosphatase inhibitors |
| EP4211119A1 (en) * | 2020-09-02 | 2023-07-19 | Merck Sharp & Dohme LLC | 2-aminoquinazolines as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69434721T2 (de) | 1993-10-01 | 2006-11-09 | Novartis Ag | Pharmacologisch wirksame pyrimidinderivate und verfahren zu deren herstellung |
| US5612340A (en) | 1993-10-01 | 1997-03-18 | Ciba-Geigy Corporation | Pyrimidineamine derivatives and processes for the preparation thereof |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| AU735901C (en) | 1996-12-05 | 2004-02-12 | Amgen, Inc. | Substituted pyrimidinone and pyridone compounds and methods of use |
| GB9812683D0 (en) * | 1998-06-12 | 1998-08-12 | Smithkline Beecham Plc | Novel compounds |
| US6602872B1 (en) | 1999-12-13 | 2003-08-05 | Merck & Co., Inc. | Substituted pyridazines having cytokine inhibitory activity |
| KR100521735B1 (ko) | 2000-02-25 | 2005-10-17 | 에프. 호프만-라 로슈 아게 | 아데노신 수용체 조절인자 |
| ATE284712T1 (de) | 2000-04-26 | 2005-01-15 | Eisai Co Ltd | Medizinische zusammensetzungen zur förderung der aktivierung der eingeweide |
| WO2002088079A2 (en) | 2001-05-01 | 2002-11-07 | Bristol-Myers Squibb Company | Dual inhibitors of pde 7 and pde 4 |
| WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| AU2003234628B2 (en) | 2002-05-21 | 2007-08-23 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| WO2004007468A1 (en) | 2002-07-15 | 2004-01-22 | Merck & Co., Inc. | Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes |
| TW200533357A (en) | 2004-01-08 | 2005-10-16 | Millennium Pharm Inc | 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases |
| DE602005024382D1 (de) | 2004-04-13 | 2010-12-09 | Astellas Pharma Inc | Polycyclische pyrimidine als kaliumionenkanal-modulatoren |
| US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| CA2578122A1 (en) | 2004-08-27 | 2006-03-02 | Gpc Biotech Ag | Pyrimidine derivatives |
| GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| GB0428514D0 (en) | 2004-12-31 | 2005-02-09 | Prosidion Ltd | Compounds |
| TW200716594A (en) | 2005-04-18 | 2007-05-01 | Neurogen Corp | Substituted heteroaryl CB1 antagonists |
| US7572809B2 (en) * | 2005-12-19 | 2009-08-11 | Hoffmann-La Roche Inc. | Isoquinoline aminopyrazole derivatives |
| EP1984331B1 (en) | 2006-02-16 | 2010-10-20 | Schering Corporation | Pyrrolidine derivatives as erk inhibitors |
| CA2651072A1 (en) * | 2006-05-01 | 2007-11-08 | Pfizer Products Inc. | Substituted 2-amino-fused heterocyclic compounds |
| DE102006035202A1 (de) | 2006-07-29 | 2008-01-31 | Lanxess Deutschland Gmbh | Konservierungsmittel auf Basis von Carbonsäureanhydriden |
| TWI389899B (zh) * | 2006-08-08 | 2013-03-21 | Msd Oss Bv | 具口服活性之凝血酶抑制劑 |
| EP2057141B1 (en) | 2006-08-23 | 2011-10-26 | Pfizer Products Inc. | Pyrimidone compounds as gsk-3 inhibitors |
| WO2008039882A1 (en) | 2006-09-30 | 2008-04-03 | Sanofi-Aventis U.S. Llc | A combination of niacin and a prostaglandin d2 receptor antagonist |
| JP2010514689A (ja) | 2006-12-22 | 2010-05-06 | ノバルティス アーゲー | 癌、炎症およびウイルス感染症の処置のためのｃｄｋ阻害剤としてのヘテロアリール−ヘテロアリール化合物 |
| EP2200436B1 (en) | 2007-09-04 | 2015-01-21 | The Scripps Research Institute | Substituted pyrimidinyl-amines as protein kinase inhibitors |
| BRPI0817135A2 (pt) | 2007-11-06 | 2014-10-07 | Du Pont | Composto, método de controle de doenças de plantas e composições fungicidas |
| US20090246198A1 (en) | 2008-03-31 | 2009-10-01 | Takeda Pharmaceutical Company Limited | Mapk/erk kinase inhibitors and methods of use thereof |
| CN102119152B (zh) | 2008-06-27 | 2014-07-02 | 诺华股份有限公司 | 有机化合物 |
| SG10201510696RA (en) | 2008-06-27 | 2016-01-28 | Celgene Avilomics Res Inc | Heteroaryl compounds and uses thereof |
| EP2370413B1 (en) | 2008-12-08 | 2015-08-05 | Arena Pharmaceuticals, Inc. | Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto |
| WO2012118850A1 (en) | 2011-02-28 | 2012-09-07 | Array Biopharma Inc. | Serine/threonine kinase inhibitors |
| CN103958502B (zh) * | 2011-08-04 | 2016-02-10 | 阵列生物制药公司 | 作为丝氨酸/苏氨酸激酶抑制剂的喹唑啉化合物 |
| PL3321262T3 (pl) | 2012-03-01 | 2021-06-28 | Array Biopharma, Inc. | Inhibitory kinaz serynowo/treoninowych |
-
2013
- 2013-08-27 WO PCT/US2013/056876 patent/WO2014036015A1/en active Application Filing
- 2013-08-27 JP JP2015529957A patent/JP6378182B2/ja active Active
- 2013-08-27 EP EP13759395.0A patent/EP2888247B1/en active Active
- 2013-08-27 CN CN201380051518.1A patent/CN105143200B/zh active Active
- 2013-08-27 CA CA2882750A patent/CA2882750A1/en not_active Abandoned
- 2013-08-27 RU RU2015110985A patent/RU2644947C2/ru not_active IP Right Cessation
- 2013-08-27 BR BR112015004548A patent/BR112015004548A2/pt not_active IP Right Cessation
- 2013-08-27 KR KR1020157007729A patent/KR20150047597A/ko not_active Application Discontinuation
- 2013-08-27 AR ARP130103040A patent/AR092253A1/es unknown
- 2013-08-27 US US14/011,501 patent/US9388171B2/en active Active
- 2013-08-27 MX MX2015002508A patent/MX369989B/es active IP Right Grant
- 2013-08-27 TW TW102130680A patent/TW201408658A/zh unknown
-
2015
- 2015-11-10 HK HK15111084.7A patent/HK1210174A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2644947C2 (ru) | 2018-02-15 |
| CN105143200B (zh) | 2018-10-16 |
| CA2882750A1 (en) | 2014-03-06 |
| US20140066453A1 (en) | 2014-03-06 |
| WO2014036015A1 (en) | 2014-03-06 |
| CN105143200A (zh) | 2015-12-09 |
| AR092253A1 (es) | 2015-04-08 |
| JP2015526519A (ja) | 2015-09-10 |
| TW201408658A (zh) | 2014-03-01 |
| JP6378182B2 (ja) | 2018-08-22 |
| EP2888247B1 (en) | 2020-03-25 |
| RU2015110985A (ru) | 2016-10-20 |
| US9388171B2 (en) | 2016-07-12 |
| KR20150047597A (ko) | 2015-05-04 |
| EP2888247A1 (en) | 2015-07-01 |
| BR112015004548A2 (pt) | 2017-08-08 |
| MX2015002508A (es) | 2015-10-12 |
| MX369989B (es) | 2019-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1254429A1 (zh) | 絲氨酸/蘇氨酸激酶抑制劑 | |
| HK1210174A1 (en) | Serine threonine kinase inhibitors for the treatment of hyperproliferativediseases | |
| HUS2200017I1 (hu) | Dihidronaftiridinek és rokon vegyületek, amelyek hasznosak kináz inhibitorokként proliferatív betegségek kezelésére | |
| HK1225735A1 (zh) | 絲氨酸/蘇氨酸激酶抑制劑 | |
| EP3019491A4 (en) | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | |
| HK1223877A1 (zh) | 絲氨酸/蘇氨酸激酶抑制劑 | |
| HK1211574A1 (en) | Serine threonine kinase inhibitors | |
| HK1199248A1 (zh) | 作為絲氨酸/蘇氨酸激酶抑制劑的喹唑啉化合物 | |
| ZA201604461B (en) | Serine/threonine kinase inhibitors | |
| AP2015008532A0 (en) | Syk kinase inhibitors as treatment for malaria | |
| HK1210616A1 (en) | Process for the preparation of c-fms kinase inhibitors c-fms | |
| HK1223832A1 (zh) | 用於癌症治療的激酶抑制劑 | |
| HK1222386A1 (zh) | 作爲詹納斯激酶的抑制劑的 -氰基甲基酰胺 | |
| AU2012901199A0 (en) | Kinase inhibitors for the Treatment of Cancer |